A post hoc analysis of the phase 3b JUMP trial supports the real-world use of ruxolitinib with anemia supportive care to maintain dosing and clinical outcomes in patients with myelofibrosis, offering ...

More than 80 percent of the 98,232 candidates eligible for Saturday’s nationwide mop-up Unified Tertiary Matriculation Examination failed to appear, a development the Joint Admissions and ...